Correction: Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach
Jun Chang, Shaoqing Zou, Yiwen Xiao, Du Zhu
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Correction **: ** BMC Complement Med Ther 23, 352 (2023)
https://doi.org/10.1186/s12906-023-04171-w
A correction has been made to Fig. 5. The sub-image of GAPDH (the last western blot image of Fig. 5A) was replicated and incorrectly uploaded instead of the sub-image for COL5A2 (the first line of the Fig. 5A). This error does not affect the conclusion of the publication.Fig. 5. The expressions (A) and the statistics results (B) of COL5A2, LOX, and CTGF in the western blot analysis. *Represents the P < 0.05. The A549 cells (control group) were pretreated with 10ng/ml of TGF-β1 to build the in vitro IPF model, and then the cells were treated with 1.5μmol/l of swertiamarin (test group) for 24 h. The samples for determining the expressions of COL5A2, LOX, CTGF, and GAPDH (glyceraldehyde 3-phosphate dehydrogenase) were derived from the same batch of experiments. The gels were processed in parallel
The original article [1] has been corrected.